| Primary liver cancer (PLC) is one of the most common malignant tumors, the global incidence rate is increasing year by year, HBV infection is the main reason for high incidence of PLC. Immune therapy, in particular, adoptive immunotherapy to PLC of hepatitis B has become hotspots, and adjuvant treatment of cancer patients has become an important method. The experimental and clinical reports on cultured autologous cytokine induced killer cells (CIK) and dendritic cells (DC) transfused to treat malignant tumors showed that the co-culture of CIK and DC could promote the proliferation and immune function of CIK and DC. Little research has been performed in the combination of CIK and DC to treat HB V-related primary liver cancer at home and abroad. In this study, CIK cells mixed with homologous HBsAg-loaded DC in order to provide information on the treatment of primary liver cancer and the basis for evaluation of therapy effect of CIK cells in combination with DC.In this study, the 60 HBV-related patients with PLC were selected from the Sixth People's Hospital of Shenyang since October 10,2009.30 patients were given combined treatment of CIK cells and DC, and the other 30 patients were given a single CIK cells therapy as the control group. Autologous CIK cells mixed with homologous HBsAg-loaded DC in 250ml salt water, and transfused the mixture to the patients with HBV related liver cancer. Tumor marker AFP, immune cells, HBV replication level differences and the liver function were compared. The therapeutic efficacy of CIK cells in combination with DC was obvious.Comparing pre-with post-treatment in the CIK combinated with DC group, the results showed that ALT, AST, TBil and Child-Pugh were significantly decreased(P< 0.01), ALB was significantly increased(P<0.05), the level of HBV DNA was significantly decreased(P<0.01), and the expressions of CD3, CD4, CD8, CD16, CD56, CD19+and CD28+were significantly increased(P< 0.01) in post-treatment than in pre-treatment.Comparing pre-with post-treatment in the CIK alone group, the results showed that ALT, AST and Child-Pugh were significantly decreased(P< 0.05), ALB was significantly increased(P< 0.05), the level of HBV DNA was significantly decreased(P < 0.05), and the expressions of CD3, CD8, CD16, CD56 and CD28 were significantly increased(P< 0.05) in post-treatment than in pre-treatment. The expressions of CD4,CD 19 were no obvious difference in pre-and post-treatment.Comparing the CIK combinated with DC group with CIK alone group, the results showed that ALT was significantly decreased(P< 0.01), AST and Child-Pugh were decreased(P< 0.05), CD4 was significantly increased(P< 0.05), and the expression levels of HBV DNA and AFP were no obvious difference in the CIK combinated with DC group than in CIK alone group.Comparing the differences of pre-and post-treatment of CIK combinated with DC group with of CIK alone group, the results showed that the differences of ALT,AST,GGT,ALP and PT were no significant difference(P> 0.05), there was obvious difference in the differences of Child-Pugh(P< 0.05) in the CIK combinated with DC group than in CIK alone group. The combinated treatment of CIK and DC was obviously decreased the expression levels of HBV DNA and AFP (P< 0.05), and significantly increased the amounts of CD16+and CD56+subgroups (P< 0.05).These studies showed that Single autologous CIK cells treatment or the co-treatment of CIK and DC could improve the liver function, incease the activity of immune cells, decrease the immunity inhibition of HBV related PLC and the level of AFP, improve the effect of anti-tumor, inhibit the growth and re-occurrence of tumor, and they also could inhibit the replication of HBV DNA and resist the effect of HBV. However the combination treatment has stronger effect than single autologous CIK cells treatment and no obvious side effects.Overall results of this study show that combined treatment of CIK cells and DC treatment can increase the immune cells activity, Increase or strong anti-tumor effect, HBV related PLC to improve the immune status, inhibit replication of HBVDNA, improve liver function to prevent disease progression. CIK cells and DC cells in combination therapy with anti-virus, anti-tumor dual role of CIK cells more effective than individual treatment.CIK cells and DC cells in HBV combination therapy will be associated with primary liver cancer is safe and effective method. Specific tumor antigens for DC cells and CIK cells, combination therapy, will further enhance the DC cells, CIK cell-based tumor immunotherapy efficacy to bring the Gospel to the majority of...
|
PDF Full Text Request